Chile - español - ISPC (Instituto de Salud Pública de Chile)

pharmaris chile s.p.a. - adalimumab - sin formulas

Unión Europea - español - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - el ipilimumab - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - agentes antineoplásicos - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.  yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 y 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.

Unión Europea - español - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - agentes antineoplásicos - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Venezuela - español - Instituto Nacional de Higiene

msd farmaceutica, c.a. - pembrolizumab - solucion para infusion - 100 mg / 4 ml

Chile - español - ISPC (Instituto de Salud Pública de Chile)

bristol - myers squibb de chile - ipilimumab - sin formulas

Chile - español - ISPC (Instituto de Salud Pública de Chile)

bristol - myers squibb de chile - ipilimumab - sin formulas

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

j&j productos medicos & farmaceuticos del peru s.a. - droguerÍa - golimumab - solucion inyectable - 12.5mg/1ml - por vial 4.00 ml - - golimumab

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

glaxosmithkline peru s.a. - belimumab; - polvo para concentrado para solucion para perfusion - por vial2 ml; belimumab 120.000000 mg; - belimumab

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

glaxosmithkline peru s.a. - belimumab; - polvo para concentrado para solucion para perfusion - por vial5 ml; belimumab 400.000000 mg; - belimumab

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

abbvie sas, sucursal del peru - droguerÍa - adalimumab - solución inyectable - 40mg/0.8 ml - por mililitro 0.80 ml - - adalimumab